The present invention relates to: Caenorhabditis elegans having insulin/IGF-1 receptor deficient mutant which maintains immunity and inhibits developmental defects; a manufacturing method thereof; and a method for screening a candidate treatment agent of insulin/IGF-1 signal transduction diseases using the Caenorhabditis elegans. A PTEN^C150Y mutant Caenorhabditis elegans animal model provided in the present invention can specifically reduce developmental defects without affecting excellent immunity of an existing insulin/IGF-1 receptor deficient mutant, thereby obviously identifying how immunity, aging, development are each controlled in an insulin/IGF-1 signal transduction system. Moreover, according to the present invention, it is expected that the present invention can contribute greatly to various research fields such as immunity enhancement and anti-aging drug development related to the insulin/IGF-1 signal transduction system.;COPYRIGHT KIPO 2017
展开▼